SQZ Biotechnologies Co·4

Jun 3, 4:39 PM ET

Warren Marshelle Smith 4

4 · SQZ Biotechnologies Co · Filed Jun 3, 2022

Insider Transaction Report

Form 4
Period: 2022-06-01
Warren Marshelle Smith
Chief Medical Officer
Transactions
  • Award

    Stock Option

    2022-06-01+200,000200,000 total
    Exercise: $3.32Exp: 2032-06-01Common Stock (200,000 underlying)
Footnotes (1)
  • [F1]The option vests and becomes exercisable as to 25% of the underlying securities on June 1, 2023 and in 36 substantially equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION